Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies
Open Access
- 29 July 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (7) , e008505
Abstract
Background: The study summarizes the potential use of immunotherapy for BRAF-mutated papillary thyroid cancer (PTC) by analyzing the immune profile of City of Hope PTC patient samples and comparing them to the thyroid dataset available in the TCGA database. Materials and methods: PTC cases with available formalin-fixed paraffin-embedded archived tumor tissue were identified. RNA was extracted from the tumor tissue and analyzed by NanoString to evaluate their immune gene expression profile. Immunohistochemistry was used to determine the expression of immune suppressive genes and lymphocytic infiltration into the tumor tissue. Thyroid cancer cell lines (MDA-T32, MDA-T68, MDA-T85, and MDA-T120) were used to determine the correlation between the BRAF inhibition and CD274 expression. Results: The study found that PTC cases with BRAF mutations had higher expression of immune checkpoint markers CD274 and CTLA4, as well as higher tumor-infiltrating lymphocytes, particularly CD4+T cells. Additionally, the study identified immunosuppressive markers expressed by tumor cells like CD73, CD276, and CD200 that could be targeted for immunotherapy. Further experiments using PTC cell lines lead to the conclusion that CD274 expression correlates with BRAF activity and that inhibitors of BRAF could potentially be used in combination with immunotherapy to treat PTC. Conclusions: These findings suggest that PTC cases with BRAF mutations or high expression may be correlated with an immune hot signature and could benefit from immunotherapeutic strategies.Keywords
Funding Information
- City of Hope Excellence Award (Excellence Project 2009957)
- Deepak Chopra (Philanthropy grant)
This publication has 57 references indexed in Scilit:
- Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 studyCancer, 2023
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced MelanomaJAMA Oncology, 2020
- MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cellsThe Journal of Pathology, 2019
- Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation statusHead & Neck, 2019
- PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid CarcinomaEndocrine Pathology, 2018
- Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibitionMolecular Oncology, 2017
- Genomic Landscape of poorly Differentiated and Anaplastic Thyroid CarcinomaEndocrine Pathology, 2016
- BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinomaHead & Neck, 2015
- Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential TargetsPathology and Oncology Research, 2015
- Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005Cancer, 2009